Johnson & Johnson reported two Phase 3 data sets showing Tecvayli (a bispecific T-cell engager) produced substantial clinical benefits when used earlier in multiple myeloma. In MajesTEC-9, J&J randomized 614 relapsed patients and said Tecvayli reduced the risk of disease progression or death compared with standard regimens; trial monitors detected benefit at an early interim check. Separately, a related Phase 3 program showed a sizable reduction in mortality, prompting J&J to plan regulatory discussions and to present the data at a future medical meeting. These results underpin J&J’s strategy to expand Tecvayli from a later-line accelerated approval into earlier treatment lines, and the company has already received heightened regulatory engagement from the FDA on related development pathways. Clarification: Progression-free survival (PFS) measures the time patients live without disease worsening and is a standard endpoint for oncology approvals. Sponsors will now weigh regulatory steps, label expansion strategies, and potential combinations with existing J&J franchises as they prepare filings and advisory communications.